Foundation Medicine Reaches 100 Approved Companion Diagnostic Indications
The precision medicine company now has 57 approvals in the US and 43 in Japan for its FoundationOne CDx and FoundationOne Liquid CDx tests.
Read MorePosted by CLP Edit Staff | Dec 8, 2025 | Molecular Diagnostics |
The precision medicine company now has 57 approvals in the US and 43 in Japan for its FoundationOne CDx and FoundationOne Liquid CDx tests.
Read MorePosted by CLP Edit Staff | Dec 4, 2025 | Womens Health |
The test uses microRNA analysis and AI to diagnose endometriosis in women with chronic pelvic pain when imaging is inconclusive.
Read MorePosted by CLP Edit Staff | Dec 3, 2025 | Prostate |
The test receives premarket approval as an aid in biopsy decision-making for men 50 and older with elevated PSA levels.
Read MorePosted by CLP Edit Staff | Dec 1, 2025 | Molecular Diagnostics |
The proposed order would shift these test systems to Class II with special controls, replacing the current PMA requirement for companion diagnostics and related oncology assays.
Read MorePosted by CLP Edit Staff | Nov 25, 2025 | Lung Cancer |
The Mercy Halo test demonstrates performance similar to low-dose CT screening with the potential to reach underscreened populations.
Read More